癌診断技術の世界市場:ELISA、ELFA、PCR、NGS、免疫組織化学、マイクロアレイ、画像診断

◆英語タイトル:Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020
◆商品コード:MAM-MD-3480
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2015年6月10日
◆ページ数:181
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、癌診断技術の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、市場シェア分析、技術別分析、用途別分析、地域別分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

According to the CDC, cancer is the second leading cause of mortality, causing ~584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR). Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.

The instrument-based cancer diagnostics segment accounted for the largest share of the global the cancer diagnostics market, by technology, while breast cancer accounted for the largest share of the cancer diagnostics applications market, in 2014.

North America accounted for the largest share of the global cancer diagnostics market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China. These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market.

The global cancer diagnostics market witnesses high competitive intensity as there are several big and many small firms operating in different segments of the market. These companies adopt various strategies (agreements/partnerships/joint ventures/collaborations, new product launches, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the cancer diagnostics market. The report analyzes cancer diagnostics by technology, application, and geography
• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cancer diagnostics market
• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cancer diagnostic technologies across regions
• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the cancer diagnostics market
• Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the cancer diagnostics market

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 19)
2.1.1 Research Methodology Steps
2.1.2 Secondary and Primary Research Methodology
2.1.2.1 Secondary Research
2.1.2.2 Key Data From Secondary Sources
2.1.2.3 Primary Research
2.1.2.4 Key Industry Insights
2.1.5 Key Data From Primary Sources
2.1.6 Key Insights From Primary Sources
2.1.7 Market Size Estimation Methodology
2.1.8 Market Forecast Methodology
2.1.9 Market Data Validation and Triangulation
2.1.10 Assumptions for the Study

3 Executive Summary (Page No. – 32)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 38)
4.1 Global Cancer Diagnostics Market
4.2 Regional Snapshot of the Cancer Diagnostics Market
4.3 Cancer Diagnostics Market, By Technology (2015 vs. 2020)

5 Market Overview (Page No. – 42)
5.1 Key Findings
5.2 Introduction
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Cancer
5.3.1.2 Technological Advancements
5.3.1.3 Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
5.3.1.4 Growth in the Number of Private Diagnostic Centers
5.3.1.5 Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
5.3.1.6 Fda Support for Biomarker Development
5.3.1.7 Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
5.3.2 Restraints
5.3.2.1 High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
5.3.2.2 Shortage of Helium
5.3.2.3 High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
5.3.2.4 Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
5.3.2.5 Dearth of Skilled and Experienced Personnel
5.3.3 Opportunities
5.3.3.1 Personalized Medicine
5.3.3.2 Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
5.3.3.3 Companion Diagnostics
5.3.3.4 Improving Healthcare Infrastructure in Emerging Markets
5.3.3.5 Miniaturized and Technologically Advanced Devices
5.3.4 Challenges
5.3.4.1 Stringent Regulatory Guidelines
5.3.4.2 Hospital Budget Cuts A Key Challenge to Market Players
5.3.4.3 Increasing Adoption of Refurbished Diagnostic Imaging Systems

6 Global Cancer Diagnostics Market, By Technology (Page No. – 60)
6.1 Introduction
6.2 Platform-Based Diagnostics
6.2.1 Polymerase Chain Reaction (PCR)
6.2.2 in Situ Hybridization (ISH)
6.2.3 Immunohistochemistry (IHC)
6.2.4 Next-Generation Sequencing (NGS)
6.2.5 Microarrays
6.2.6 Flow Cytometry
6.2.7 Other Technologies
6.3 Instrument-Based
6.3.1 Diagnostic Imaging
6.3.1.1 Magnetic Resonance Imaging (MRI)
6.3.1.2 Computed Tomography (Ct)
6.3.1.3 Positron Emission Tomography (PET)
6.3.1.3.1 Standalone Positron Emission Tomography
6.3.1.3.2 Hybrid Positron Emission Tomography
6.3.1.4 Mammography
6.3.1.5 Ultrasound
6.3.2 Biopsies

7 Global Cancer Diagnostics Market, By Application (Page No. – 84)
7.1 Introduction
7.1.1 Breast Cancer
7.1.2 Lung Cancer
7.1.3 Colorectal Cancer
7.1.4 Melanoma
7.1.5 Other Cancers

8 Market, By End User (Page No. – 93)

9 Cancer Diagnostics Market, By Region (Page No. – 95)
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.1.1 Government Initiatives
9.2.1.2 Increase in Cancer Incidence
9.2.2 Canada
9.2.2.1 High Incidence of Cancer
9.2.2.2 Government Funding
9.3 Europe
9.3.1 Funding for Cancer Diagnostics Research
9.3.2 Eu-5 (U.K., Germany, France, Italy, Spain)
9.3.2.1 Strong Government Support
9.3.2.2 Research Collaborations
9.3.2.3 Increase in Diagnostic Imaging Centers
9.3.2.4 Rising Public and Private Investments
9.3.3 Rest of Europe (RoE)
9.3.3.1 Aging Population
9.3.3.2 Conferences Boosting Awareness
9.3.3.3 Government Investments in Russia
9.4 Asia
9.4.1.1 China
9.4.1.1.1 Expansion of International Players
9.4.1.1.2 Aging Population and Increasing Cancer Incidence
9.4.1.2 Japan
9.4.1.2.1 Aging Population and High Healthcare Expenditure in Japan
9.4.1.3 India
9.4.1.3.1 Increasing Focus of International Players on India
9.4.1.4 Rest of Asia
9.4.1.4.1 Presence of International Players Boosting Market Growth
9.5 Rest of the World (RoW)
9.5.1.1 Government Initiatives Boosting Demand for Cancer Diagnostics
9.5.1.2 Aging Population, Presence of International Players
9.5.1.3 Increase in Cancer Incidences and Rising Government Expenditure
9.5.1.4 Government Initiatives to Improve Healthcare Infrastructure

10 Competitive Landscape (Page No. – 138)
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 Collaborations/Agreements/Partnerships/Alliances
10.3.2 New Product Launches
10.3.3 Acquisitions
10.3.4 Expansion
10.3.5 Others

11 Company Profiles (Page No. – 153)
11.1 Introduction
11.3 Becton, Dickinson and Company
11.3.1 Business Overview
11.3.2 Product Portfolio
11.3.3 Key Strategy
11.3.4 Recent Developments
11.4 GE Healthcare (A Subsidiary of General Electric Company)
11.4.1 Business Overview
11.4.2 Product Portfolio
11.4.3 Key Strategy
11.4.4 Recent Developments
11.5 Abbott
11.5.1 Business Overview
11.5.2 Product Portfolio
11.5.3 Key Strategy
11.5.4 Recent Developments
11.6 Roche
11.6.1 Business Overview
11.6.2 Product Portfolio
11.6.3 Key Strategy
11.6.4 Recent Developments
11.7 Thermo Fisher Scientific, Inc.
11.7.1 Business Overview
11.7.2 Thermo Fisher Scientific, Inc.: Company Snapshot
11.7.3 Product Portfolio
11.7.4 Key Strategy
11.7.5 Recent Developments
11.8 Agilent Technologies, Inc.
11.8.1 Business Overview
11.8.2 Agilent Technologies, Inc.: Company Snapshot
11.8.3 Product Portfolio
11.8.4 Key Strategy
11.8.5 Recent Developments
11.9 Illumina, Inc.
11.9.1 Business Overview
11.9.2 Product Portfolio
11.9.3 Key Strategy
11.9.4 Recent Developments
11.10 Siemens Healthcare
11.10.1 Business Overview
11.10.2 Product Portfolio
11.10.3 Key Strategy
11.10.4 Recent Developments
11.11 C.R. Bard, Inc.
11.11.1 Business Overview
11.11.2 Product Portfolio
11.11.3 Key Strategy
11.11.4 Recent Developments

12 Appendix (Page No. – 190)
12.1 Discussion Guide
12.2 Available Customizations
12.3 Related Reports
12.4 Introducing RT: Real-Time Market Intelligence

List of Tables (89 Tables)

Table 1 Rising Prevalence of Cancer is Driving the Growth of the Cancer Diagnostics Market
Table 2 High Capital Investment Restraining the Growth of this Market
Table 3 Emerging Markets Present an Array of Opportunities for the Growth of this Market
Table 4 Stringent Regulatory Guidelines are A Major Challenge in the Cancer Diagnostics Market
Table 5 Global Cancer Diagnostics Market Size, By Technology, 2013–2020 ($Million)
Table 6 Global Market Size, By Technology, 2013–2020 ($Million)
Table 7 Market Size for Platform-Based Diagnostics, By Region, 2013–2020 ($Million)
Table 8 Global Market Size for PCR, By Region, 2013–2020 ($Million)
Table 9 Global Market Size for PCR, By Application, 2013–2020 ($Million)
Table 10 Cancer Diagnostics Market Size for in Situ Hybridization, By Region, 2013-2020 ($Million)
Table 11 Global Market Size for in Situ Hybridization, By Application, 2013–2020 ($Million)
Table 12 Market Size for Immunohistochemistry, By Region, 2013–2020 ($Million)
Table 13 Global Market Size for Immunohistochemistry, By Application, 2013–2020 ($Million)
Table 14 Market Size for NGS, By Region, 2013–2020 ($Million)
Table 15 Global Market Size for NGS, By Application, 2013–2020 ($Million)
Table 16 Market Size for Microarrays, By Region, 2013–2020 ($Million)
Table 17 Global Market Size for Microarrays, By Application, 2013–2020 ($Million)
Table 18 Market Size for Flow Cytometry, By Region, 2013–2020 ($Million)
Table 19 Global Market Size for Flow Cytometry, By Application, 2013–2020 ($Million)
Table 20 Market Size for Other Technologies, By Region, 2013–2020 ($Million)
Table 21 Global Market Size for Other Technologies, By Application, 2013–2020 ($Million)
Table 22 Global Market Size, By Technology, 2013–2020 ($Million)
Table 23 Cancer Diagnostics Market Size for Diagnostic Imaging, By Product, 2013–2020 ($Million)
Table 24 Market Size for Diagnostic Imaging, By Region, 2013–2020 ($Million)
Table 25 Global Market Size for Imaging, By Application, 2013–2020 ($Million)
Table 26 Cancer Diagnostics Market Size for MRI, By Region, 2013–2020 ($Million)
Table 27 Market Size for CT, By Region, 2013–2020 ($Million)
Table 28 Market Size for PET, By Product, 2013–2020 ($Million)
Table 29 Market Size for PET, By Region, 2013–2020 ($Million)
Table 30 Market Size for Standalone PET, By Region, 2013–2020 ($Million)
Table 31 Market Size for Hybrid PET, By Region, 2013–2020 ($Million)
Table 32 Market Size for Mammography, By Region, 2013–2020 ($Million)
Table 33 Market Size for Ultrasound, By Region, 2013–2020 ($Million)
Table 34 Cancer Diagnostics Market Size for Biopsy, By Region, 2013–2020 ($Million)
Table 35 Global Market Size for Biopsy, By Application, 2013–2020 ($Million)
Table 36 Global Market Size, By Application, 2013–2020 ($Million)
Table 37 Market Size for Breast Cancer, By Region, 2013–2020 ($Million)
Table 38 Market Size for Lung Cancer, By Region, 2013–2020 ($Million)
Table 39 Market Size for Colorectal Cancer, By Region, 2013–2020 ($Million)
Table 40 Market Size for Melanoma, By Region, 2013–2020 ($Million)
Table 41 Cancer Diagnostics Market Size for Other Cancers, By Region, 2013–2020 ($Million)
Table 42 North America Market, By Country, 2013–2020 ($Million)
Table 43 North America: Market, By Technology, 2013–2020 ($Million)
Table 44 North America: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 45 North America: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 46 North America: Market, By Application, 2013–2020 ($Million)
Table 47 U.S.: Market, By Technology, 2013–2020 ($Million)
Table 48 U.S.: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 49 U.S.: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 50 Canada: Market, By Technology, 2013–2020 ($Million)
Table 51 Canada: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 52 Canada: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 53 Europe: Market, By Region, 2013–2020 ($Million)
Table 54 Europe: Market, By Technology, 2013–2020 ($Million)
Table 55 Europe: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 56 Europe: Cancer Diagnostics Instrument Market, By Technology, 2013–2020 ($Million)
Table 57 Europe: Market, By Application, 2013–2020 ($Million)
Table 58 EU-5: Market, By Technology, 2013–2020 ($Million)
Table 59 EU-5: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 60 EU-5: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 61 RoE: Market, By Technology, 2013–2020 ($Million)
Table 62 RoE: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 63 RoE: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 64 Asia: Market, By Country, 2013–2020 ($Million)
Table 65 Asia: Market, By Technology, 2013–2020 ($Million)
Table 66 Asia: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 67 Asia: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 68 Asia: Market, By Application, 2013–2020 ($Million)
Table 69 China: Market, By Technology, 2013–2020 ($Million)
Table 70 China: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 71 China: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 72 Japan: Market, By Technology, 2013–2020 ($Million)
Table 73 Japan: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 74 Japan: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 75 India: Market, By Technology, 2013–2020 ($Million)
Table 76 India: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 77 India: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 78 RoA: Market, By Technology, 2013–2020 ($Million)
Table 79 RoA: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 80 RoA: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 81 RoW: Market, By Technology, 2013–2020 ($Million)
Table 82 RoW: Cancer Diagnostics Platform-Based Market, By Technology, 2013–2020 ($Million)
Table 83 RoW: Cancer Diagnostics Instrument-Based Market, By Technology, 2013–2020 ($Million)
Table 84 RoW: Market, By Application, 2013–2020 ($Million)
Table 85 Collaborations/Agreements/Partnerships/Alliances, 2012-2015
Table 86 New Product Launches, 2012–2015
Table 87 Acquisitions, 2012–2015
Table 88 Expansions, 2012–2015
Table 89 Other Strategies, 2012–2015

List of Figures (37 Figures)

Figure 1 Cancer Diagnostics Market Segmentation
Figure 2 Global Cancer Diagnostics Market : Research Methodology Steps
Figure 3 Sampling Frame: Primary Research
Figure 4 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Size Estimation Methodology: Bottom-Up Approach
Figure 6 Market Size Estimation Methodology: Top-Down Approach
Figure 7 Market Forecast Methodology
Figure 8 Data Triangulation Methodology
Figure 9 Platform-Based Diagnostics to Witness Highest CAGR of 25.3% From 2015 to 2020
Figure 10 Global Platform-Based Cancer Diagnostics Market Share, By Technology, 2015–2020
Figure 11 Global Cancer Diagnostics Market, By Geography
Figure 12 Largest and Fastest-Growing Cancer Diagnostic Applications, 2015-2020
Figure 13 Cancer Diagnostics Market Likely to Grow at A CAGR of 12.9% in the Forecast Period
Figure 14 Market, By Region and Application: North America Will Dominate the Cancer Diagnostics Market in 2015
Figure 15 Asia to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Instrument-Based Technology Will Command Largest Market Share
Figure 17 Market: Drivers, Restraints, Opportunities, & Challenges
Figure 18 NGS, A Ground-Breaking Technology in Cancer Diagnosis
Figure 19 Ultrasound Accounted for the Largest Share of the Cancer Diagnostics Market for Imaging
Figure 20 Market Growth Will Be Driven By Rising Incidence & Prevalence of Breast and Lung Cancers
Figure 21 Lung Cancer Application is Expected to Grow at the Highest CAGR in the Forecast Period
Figure 22 New Product Launches Was the Key Growth Strategy for Market Players
Figure 23 Global NGS Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
Figure 24 Global Microarrays Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
Figure 25 Global Flow Cytometry (For Cancer Diagnostics) Market Share Analysis, By Key Player, 2014
Figure 26 Global MRI Imaging Market Share Analysis, By Key Player, 2014
Figure 27 Global CT Imaging Market Share Analysis, By Key Player, 2014
Figure 28 Global PET Imaging Market Share Analysis, By Key Player, 2014
Figure 29 Global Ultrasound Imaging Market Share Analysis, By Key Player, 2014
Figure 30 Battle for Market Share: Collaborations/Agreements/Partnerships/ Alliances Were Key Strategies
Figure 31 Becton, Dickinson and Company: Company Snapshot
Figure 32 GE Healthcare: Company Snapshot
Figure 33 Abbott: Company Snapshot
Figure 34 Roche Diagnostics: Company Snapshot
Figure 35 Illumina, Inc.: Company Snapshot
Figure 36 Siemens: Company Snapshot
Figure 37 C.R. Bard, Inc.: Company Snapshot

【レポートのキーワード】

癌診断技術、癌検査、ELISA、ELFA、PCR(ポリメラーゼ連鎖反応)、NGS(次世代シーケンシング)、免疫組織化学、マイクロアレイ、画像診断、癌診断技術用途、乳がん診断、肺がん診断、大腸癌診断、黒色腫診断

★調査レポート[癌診断技術の世界市場:ELISA、ELFA、PCR、NGS、免疫組織化学、マイクロアレイ、画像診断] (コード:MAM-MD-3480)販売に関する免責事項を必ずご確認ください。
★調査レポート[癌診断技術の世界市場:ELISA、ELFA、PCR、NGS、免疫組織化学、マイクロアレイ、画像診断]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆